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Abstract 
The classification of human tumors based on molecular criteria offers tremendous 
clinical potential; however, discerning critical and ‘druggable’ effectors on a large scale 
will also require robust experimental models reflective of tumor genomic diversity.  Here, 
we describe a comprehensive genomic analysis of 89 melanoma short-term cultures and 
cell lines.  Using an analytical approach designed to enrich for putative ‘driver’ events, 
we show that cultured melanoma cells encompass the spectrum of significant genomic 
alterations present in primary tumors.  When annotated according to these lesions, 
melanomas clustered into subgroups indicative of distinct oncogenic mechanisms.  
Integrating gene expression data suggests novel tumor-promoting mechanisms, as 
exemplified by chromosome 10 deletions.  Finally, sample-matched pharmacologic data 
shows that FGFR1 mutations and ERK activation may modulate tumor sensitivity to MEK 
inhibitors.  Genetically-defined cell culture collections may therefore offer a rich 
framework for systematic functional studies in melanoma and other tumors.  
 
Introduction 
The recognition that cancer is fundamentally a genetic disease1,2, combined with an expanding 
repertoire of targeted small molecules3-8, provides grounds for optimism that genome-based 
therapeutics may ultimately prove broadly applicable to human cancer.  However, the rational 
deployment of targeted anti-cancer agents is often encumbered by an inability to identify a priori 
those tumors whose unique biology confers heightened susceptibility to a particular treatment.  
Considerable insights into tumorigenesis have derived from functional studies involving cultured 
human cancer cells (e.g., established cell lines, short-term cultures, etc.); however, the overall 
relevance of tissue culture models to the complexities of in vivo tumor biology has often been 
questioned.  Despite their limitations, cancer cell line collections whose genetic alterations 
reflect their primary tumor counterparts should nonetheless provide malleable proxies that 
facilitate mechanistic dissection and therapeutic development.  Indeed, matched genomic and 
experimental data derived from these models may refine hypothesis generation and reveal new 
insights, as evidenced by recent studies9,10.  Such results may also be integrated with 
analogous data from clinical specimens to infer molecular subtypes and therapeutic 
vulnerabilities in tumors that manifest the relevant genomic changes11-13. 
 
When it escapes early detection, malignant melanoma usually becomes a highly lethal 
malignancy that is refractory to existing therapeutic avenues14,15.  However, whereas many 
other solid tumors lack robust in vitro counterparts, melanoma offers an attractive experimental 
platform for systematic functional characterization of cancer genomic aberrations.  Melanoma 
cells from patients with advanced disease proliferate readily in vitro; thus, hundreds of ‘short-
term’ melanoma cultures and established cell lines have been generated16-18.  Melanoma short-
term cultures have typically undergone a relatively small number of passages outside of the 
patient, and the majority of these lines proliferate readily under standard laboratory conditions.  
In principle, then, a cultured melanoma collection that reflects the diversity of genomic 
aberrations observed in primary melanomas should facilitate the characterization of critical and 
‘druggable’ effectors linked to key molecular lesions in this malignancy.  
 
Results 
The genomic diversity of melanoma in vitro and in vivo 
To enhance global knowledge of melanoma genomic alterations while also establishing a robust 
experimental system for downstream functional characterization, we generated comprehensive 
genomic data for 78 short-term melanoma cultures (median = 9 passages in vitro; range = 5-
51), together with 11 established melanoma cell lines.  Chromosomal copy number and loss-of-
heterozygosity (LOH) alterations were examined using high-density single-nucleotide 
polymorphism (SNP) arrays9,19,20, and the mutation status of 17 known oncogenes was 
interrogated by Sanger sequencing or a mass spectrometry-based mutation profiling approach 
described previously21.  Gene expression patterns were determined for 88 cultured melanoma 
lines and 5 normal melanocyte lines using a high-throughput microarray platform22 (Affymetrix, 
Inc.; see Methods).  Altogether, 118 cultured melanoma lines were examined by one or more of 
these platforms.   
 
Since tumor chromosomal alterations are often non-focal, we next wished to predict which 
genetic changes represented statistically significant events (presumably enriched for “driver” 
alterations) in melanoma.  To accomplish this, we employed an algorithm termed Genomic 
Identification of Significant Targets in Cancer (GISTIC; Beroukhim et al., submitted).  This 
method systematically computes a significance score at each locus across the genome using 
smoothed microarray/CGH copy number data, based on the frequency and amplitude of each 
alteration (G score; see Methods).  After permutation testing and multiple hypothesis correction, 
resulting false discovery rate (FDR)-corrected p values are plotted as a function of chromosomal 
location.  Significant genomic regions of gain or loss are denoted by peaks in the GISTIC plot; 
the underlying chromosomal regions may then be inspected for candidate target genes. 
 
The GISTIC output revealed thirteen major regions of significant copy number gain and fourteen 
regions of significant copy loss in the cultured melanoma collection (Figs. 1a and 1b; Tables 1 
and 2).  The most significant region of copy gain was located on chromosome 7q (Fig. 1a).  This 
locus harbors the BRAF oncogene, which contains activating point mutations in >50% of 
cutaneous melanomas23 and in 60% of samples examined here.  This suggests that mutated 
BRAF is also frequently amplified in melanoma.  Additional prominent GISTIC copy gain peaks 
localized exquisitely to MITF, the master transcriptional regulator of melanocyte development 
and an amplified oncogene in 10-15% of melanomas9; and to CCND1, a well-known oncogenic 
cell cycle regulator (Fig. 1a).  The most prominent region of copy loss spanned CDKN2A, an 
established melanoma tumor suppressor gene24,25 (Fig. 1b).  Aside from these expected 
findings, the majority of GISTIC peaks pinpointed genomic regions implicated previously in 
melanoma26-28 (Supplementary Fig. 1), but whose target genes remain largely unknown (Tables 
1 and 2).  Integration of sample-matched gene expression data enabled identification of 
candidate effector genes in several instances (Tables 1 and 2).  Thus, GISTIC analysis afforded 
a robust and unbiased means to identify key genomic loci whose target genes may contribute 
importantly to melanoma biology.   
 
Theoretically, cultured human cancer cell collections may represent a biased malignant subset 
that fail to encompass the pathophysiology relevant in primary tumors.  To address this at a 
genomic level in cutaneous melanoma, we performed GISTIC analysis on bacterial artificial 
chromosome (BAC) array CGH data derived from 70 primary cutaneous melanomas (Curtin ref; 
see Methods) and compared the resulting significance values to those observed in primary 
tumors.  As shown in Figs. 1a and 1b, the landscape of genomic alterations was strikingly 
similar between cultured cells and primary tumors, even with respect to subtle contours within 
the GISTIC plots.  Some significant alterations present in cultured cells were absent in primary 
tumors (e.g., gains on chromosome 3p14 (MITF) and chromosome 15q, and a region of loss on 
4q); in most cases, these were attributable to low BAC clone coverage in the primary tumor 
data.  Conversely, a single GISTIC peak centered on chromosome 13q33 exhibited reduced 
significance in cultured cells compared to primary tumors.  Interestingly, the underlying 3.2 Mb 
locus spanned the ERCC5 excision repair gene, and this deletion showed marked enrichment in 
primary melanomas from chronic sun-damaged (CSD) skin26 (Supplementary Figure 2a, 2b, 2c).  
These findings raised the possibility that deletions involving ERCC5 may contribute to 
melanoma genesis in the setting of chronic sun damage.   
 
To confirm the similarities between cultured melanoma cells and primary melanomas, we 
performed pair-wise Pearson correlations between GISTIC plots of cultured melanoma data, 
primary melanomas, and a series of additional solid tumors whose chromosomal aberrations 
had been examined previously (Supplementary Table 1).  Notably, GISTIC correlations between 
cultured melanoma cells and primary cutaneous melanomas from non-CSD skin were stronger 
than any pair-wise coefficient observed among all other primary tumor sets, thereby providing a 
rigorous quantitative metric of genomic similarity. These data suggested that, in aggregate, 
cultured melanoma collections might provide a genetically appropriate model system for 
systematic functional genomic characterization.   
 
Genome-wide measurements of loss-of-heterozygosity (LOH) in melanoma 
High-density SNP arrays also enable inference of LOH29, even in the absence of matched 
normal DNA30.  To identify significant LOH regions within our cultured melanoma collection, we 
predicted LOH patterns within each sample using a hidden Markov model30, and applied the 
GISTIC algorithm to the resulting LOH segments (see Methods).  A strong concordance was 
observed between regions of LOH and copy loss (Fig. 1c), suggesting that most melanoma 
LOH events occur by hemizygous deletion.  The major exceptions to this pattern occurred at 
chromosomes 5q and 17p, where LOH in the absence of significant hemizygous deletion 
(“copy-neutral” LOH) was apparent.  Although the relevant tumor suppressor at chromosome 5q 
has not been identified, the LOH peak at chromosome 17p centers on the well-known TP53 
tumor suppressor gene (Fig 1c).  This suggests that copy-neutral LOH may represent an 
important mechanism of p53 inactivation in melanoma.  In a subset of short-term culture 
samples, a segment of chromosome 4q appeared to contain significant hemizygous deletion in 
the absence of LOH (Fig. 1c).  This unusual phenomenon, which could occur by whole genome 
duplication followed by copy loss and biallelic retention, implies that this region of the melanoma 
genome might be relatively refractory to LOH or uniparental disomy.   
 Molecular classification of melanoma based on chromosomal aberrations 
We next sought to determine if significant chromosomal events might organize the melanoma 
samples into molecularly distinct and/or biologically relevant subsets. To address this, we 
applied established unsupervised learning methods31 to the lesions identified by GISTIC (see 
Methods).  As shown in Figure 2a, hierarchical clustering grouped GISTIC-annotated cultured 
melanoma samples into four main branches.  The major subcluster (n = 33 samples; Fig. 2a, 
cluster #3) was enriched for several prevalent alterations, most notably gains on chromosome 
7p/7q and losses on 9p21, 4q34, and 10p/10q.  This subcluster was associated with a marked 
enrichment in BRAF mutation compared to NRAS mutation in both the cultured and primary 
melanoma sets (Fig. 2a), thereby highlighting the observation that mutated BRAF is commonly 
amplified, at least to low levels, in melanoma (Supplementary Fig. 3c, 3d, 3e).   
 
A second major subcluster (n = 24 samples; Fig. 2a, cluster #4) was characterized by 
essentially the same genomic alterations, except for the notable absence of chromosome 10 
deletions.  NRAS mutations exhibited a higher prevalence in this subcluster than in cluster #3 
(Fig. 2a).  Nonetheless, this cluster was also characterized by a high frequency of 7q gain, even 
in the setting of NRAS mutation, suggesting that BRAF-independent effectors located on 
chromosome 7q may also contribute to melanoma biology.  A third group (n=20 samples) was 
characterized by a relative paucity of copy number alterations (“sparse”; Fig. 2a, cluster #1).  
Finally, a relatively small branch (n = 13 samples, cluster #2) was moderately enriched for gains 
at 6p, 17q and 7p, and losses on 6q.  Overall, these results suggested that GISTIC lesions may 
promote biologically relevant molecular groupings of melanoma tumor samples.  
 
Predicting genes targeted by chromosome 10 deletions in melanoma 
In melanoma, as in many solid tumors, most statistically significant chromosomal aberrations 
span large genomic regions whose target genes are unknown26-28.  Among many other lesions, 
this pattern is exemplified by the gains and losses involving chromosomes 7 and 10, 
respectively—two prominent drivers of the GISTIC-based melanoma subclusters described 
above.  Although the most significantly “amplified” region on chromosome 7 centers at 7q34 
(contains BRAF; Fig. 1a), most chromosome 10 copy losses cover the entire chromosome, 
punctuated by a more focal GISTIC peak at 10q23.31 (Fig. 1b and Supplementary Figure 1a 
and 1b) spanning the PTEN tumor suppressor gene.  To a first approximation, these 
observations are consistent with a model in which chromosome 7 gains and 10 deletions 
enhance oncogenic BRAF and diminish PTEN expression, thereby suggesting cooperating 
effects of these two cancer genes in melanoma, as suggested previously32.  On the other hand, 
whereas chromosome 10 deletions are highly prevalent even in early-stage melanomas26 
(Figure 1b), the relative contribution of PTEN inactivation in melanoma establishment remains 
unclear.   
 
To investigate this, we examined whether pan-chromosome 10 deletions were associated with 
functional PTEN inactivation, either through genetic mutation or mRNA/protein loss.  As shown 
in Figure 3a, only five of 89 short-term cultures and cell lines with chromosome 10 deletions 
also contained focal PTEN homozygous deletions; similar results were observed in an 
independent melanoma cell line panel described previously (Supplementary Figure 3a).  
Consistent with prior DNA sequencing analyses of short-term melanoma cultures and primary 
tumors33,34, only 5 of 98 lines examined here contained inactivating PTEN mutations; and only 
two of these samples also harbored hemizygous loss or LOH of chromosome 10.  Using 
sample-matched gene expression data, we then examined PTEN mRNA expression in relation 
to genomic deletion.  Here, whereas PTEN homozygous deletion correlated with a marked 
reduction in PTEN expression, <50% of samples with hemizygous deletions exhibited 
decreased PTEN levels when compared to samples without alterations at this locus (Fig. 3B).  
Similar results were observed following immunoblot analysis of PTEN protein levels in a subset 
of samples (Fig. 3c).  These observations raised the possibility that an as-yet uncharacterized 
tumor suppressor gene(s) located on chromosome 10 might promote tumor establishment in a 
large fraction of melanomas.   
 
To identify additional candidate tumor suppressor genes enacted by non-focal chromosome 10 
deletions in a non-biased manner, we partitioned our samples into tertiles based on the ranked 
magnitude of chromosome 10 loss (see Methods) and segregated the two extreme tertiles 
according to the class distinction ‘chromosome 10-deleted’ (20 samples) versus ‘chromosome 
10-wild-type’ (21 samples).  We then performed a genome-wide significance analysis (SAM) 
using sample-matched gene expression data.  As shown in Fig. 3d, 43 unique transcripts 
exhibited significantly diminished expression in association with chromosome 10 deletion at a 
delta value of 1.344 (median false number of genes = 0).  Interestingly, two chromosome 10 
genes with putative tumor suppressor roles—CUL2 (chromosome 10p11) and KLF6 
(chromosome 10p14)—scored in this analysis, whereas PTEN failed to reach statistical 
significance (Figure 3D).  CUL2 encodes a cullin protein whose yeast homologues negatively 
regulate the cell cycle35; CUL2 also forms an E3 ubiquitin ligase complex with the VHL tumor 
suppressor protein36,37.  KLF6 encodes a zinc-finger transcription factor implicated as a tumor 
suppressor in several malignancies38-40.  Thus, CUL2 and KLF6 represent intriguing candidate 
melanoma tumor suppressor genes targeted by chromosome 10 deletions.   
 
Modifiers of RAF/MEK dependency in melanoma 
The establishment of an experimentally tractable system reflective of melanoma genomic 
diversity provides a means to identify molecular predictors and modifiers of therapeutic 
response in this highly chemo-resistant malignancy.  Since most cutaneous melanomas harbor 
activating point mutations in BRAF or NRAS23,41 (two key effectors of the MAP kinase signaling 
cascade), several ongoing clinical trials are investigating the efficacy of RAF and MEK inhibitors 
in this setting.  To identify genetic/molecular modifiers of MAP kinase dependency that might 
influence therapeutic response, we examined cellular response to pharmacologic MAP kinase 
inhibition in a panel of 31 short-term cultures using the MEK inhibitor CI-1040.  BRAFV600E 
mutation was invariably associated with sensitivity to MEK inhibition as shown previously10 (e.g., 
sub-micromolar CI-1040 GI50 values; Figure 4A); although one BRAFV600E line (WM853-2) was 
moderately less sensitive to CI-1040.  In contrast, NRAS-mutant melanomas exhibited highly 
variable MAP kinase dependencies; whereas 4 NRAS-mutant lines with codon 61 mutations 
showed CI-1040 sensitivity patterns similar to the BRAFV600E panel, two lines harboring codon 
12/13 NRAS mutations were ‘indifferent’ to CI-1040 treatment.  PTEN protein loss was more 
common in lines showing decreased sensitivity to CI-1040 (Figure 4a).  Surprisingly, a short-
term culture harboring the BRAFK601E mutation also showed insensitivity to CI-1040.  Together, 
these data suggested the presence of additional genetic or molecular modifiers of melanoma 
MAP kinase dependency apart from BRAF or NRAS mutation. 
 
To investigate this in more detail, we examined the associated genomic and protein data in the 
melanoma lines described above.  Despite the diversity of CI-1040 GI50 values, a similar degree 
of target inhibition was evident in several representative lines, as measured by p-ERK 
immunoblotting studies (Supplementary Figure 4a).  A genome-wide analysis of correlated 
chromosomal alterations and expressed genes, summarized in Supplementary Figure 5, was 
encumbered by the relatively small CI-1040-insensitive sample size (3 samples).  However, two 
lines harboring the FGFR1S125L mutation exhibited markedly enhanced sensitivity to MEK 
inhibition when compared to the A375 control cell line (Fig. 4b).  In contrast, ‘steady-state’ 
immunoblot analyses of MEK and ERK found that p-ERK levels were markedly elevated in all 
CI-1040-insensitive lines, with concomitant downregulation of total MEK protein in the three 
most resistant lines (Figure 4c).  These data suggest the intriguing possibility that novel 
signaling or feedback regulatory mechanisms may affect MAP kinase activation/dependency in 
melanoma, and that concomitant measurement of oncogene mutations and p-ERK levels may 
refine knowledge of melanoma patients likely to respond to targeted RAF or MEK inhibition. 
 
Discussion 
The unprecedented opportunities of cancer genomics also present new challenges to the 
identification of ‘target-able’ tumor mechanisms.  In particular, characterizing the downstream 
effectors of common but often non-focal genomic alterations requires tractable in vitro models 
reflective of these genetic events.  Our global genomic analyses indicate that melanoma short-
term cultures appear to encompass the spectrum of essential genomic diversity present in 
primary cutaneous melanomas, suggesting that these may offer a robust platform for functional 
genomic characterization.  Moreover, the high-resolution statistical delineations enabled by the 
GISTIC analytical framework strongly suggests (but does not prove) that such regions contain 
genes whose perturbation contributes causally to melanoma genesis or maintenance.   
 
These analytical refinements also call renewed attention to instances where a full chromosome 
or chromosome arm displays a common tumor-associated alteration.  In melanoma, deletions 
and LOH involving chromosome 10 provide an instructive example.  Several previous studies 
have implicated inactivation of the PTEN tumor suppressor gene as a key (epi)genetic event in 
melanoma. While our results support the notion that PTEN loss provides a driver alteration in 
some melanomas, they also suggest an alternative model wherein chromosome 10 losses 
provide a polygenic or otherwise PTEN-independent melanoma genesis mechanism(s).  
Overall, the tendency towards large chromosomal perturbations in cancer underscores the 
future need for systematic functional studies in genetically-characterized tumor model systems. 
 
Application of hierarchical clustering to a matrix of GISTIC lesions yields melanoma subclasses 
whose characteristics are suggestive of mechanistic relevance.  When applied broadly in cancer 
genomics, these analyses may help reduce the complexity of cancer genome aberrations while 
also laying a robust groundwork for molecular classification and downstream functional 
approaches.  In the future, genetically annotated melanoma lines could be subjected to 
systematic RNAi studies informed by GISTIC or related statistical information.  Genes located 
within statistically credentialed genomic regions whose knockdown modulates a cancer 
phenotype of interest may illuminate ‘druggable’ cellular pathways linked to tumor genomic 
events identifiable in situ. 
 
Finally, cell culture models reflective of in vivo tumor genetic diversity offer an attractive avenue 
to identify molecular features that modify the efficacy of therapeutic agents.  In melanoma, the 
MAP kinase pathway is commonly activated by BRAF or NRAS oncogene point mutations, and 
BRAF(V600E) mutation is associated with sensitivity to RAF or MEK inhibition.  Our data 
suggest that in some contexts, NRAS or FGFR1 mutations may also confer sensitivity to MAP 
kinase pathway inhibition, but that high p-ERK may correlate with insensitivity to these 
inhibitors.  While these studies require functional validation, they demonstrate how cultured cell 
models facilitate orthogonal analyses of genomic and protein data to yield new insights into 
targeted therapeutic response.  Overall, the large-scale application of these approaches to 
genetically annotated cancer cell culture models should provide a rich framework for extraction 
of key dependencies from tumor genomic data, thereby offering new therapeutic possibilities in 
melanoma and many other solid tumors. 
 
 
Materials and Methods: 
 
Cell culture and reagents. 
Short-term melanoma cultures were selected from cryopreserved collections at the Wistar 
Institute (62 lines), the University Hospital of Zurich (24 lines), and the Dana-Farber Cancer 
Institute (32 lines).  Established melanoma cell lines were provided by Dr. Susan Holbeck 
(National Cancer Institute) and Dr. David Fisher (Dana-Farber Cancer Institute).  All cell lines 
and short-term cultures were cultured in RPMI medium (MediaTech) supplemented with 10% 
fetal bovine serum (MediaTech), except for the Dana-Farber short-term cultures, which were 
grown in Dulbecco’s modified Eagle medium (MediaTech) supplemented with 10% serum.  For 
some Wistar lines, tissue culture dishes were first coated with 1% porcine gel solution (Sigma 
#G1890-100G) to enhance cell adherence.  
 
High-density SNP array hybridization. 
Genomic DNA was prepared from near-confluent cells using the DNEasy Tissue Kit (Qiagen) 
according to the manufacturer’s instructions.  For highly pigmented cultures, 1:1 phenol-
choloroform extractions followed by centrifugation were performed prior to column purification. 
SNP array data was generated using either the StyI chip from the 500K Human Mapping Array 
set (Affymetrix, Inc.) (58 samples) or the XbaI chip from the 50K Human Mapping Array set (31 
samples). Array experiments using 250 ng of genomic DNA were carried out in 96-well format 
using a Biomek FX robot with dual 96 and span-8 heads (Beckman Coulter) and a GeneChip 
Fluidics Station FS450 (Affymetrix, Inc.), as described in Supplementary Methods.  After 
hybridization, microarrays were scanned using the GeneChip Scanner 3000 7G (Affymetrix, 
Inc.) to generate .cel and .txt files. Subsequent data processing steps are detailed in 
Supplementary Methods. 
 
High-throughput oncogene mutation profiling and DNA sequencing. 
Genomic DNA was genotyped for 238 known mutations in 17 oncogenes as described 
previously.21  Alternatively, BRAF and NRAS mutations were determined by Sanger sequencing 
(Agencourt).  All samples were sequenced for PTEN coding and splice junction mutations using 
pre-validated exon primers (Agencourt) and analyzed with Mutation Surveyor (SoftGenetics, 
LLC.).   
 
Gene expression profiling. 
RNA was purified by a TRIzol extraction protocol (Invitrogen), as described in Supplementary 
Methods.  Affymetrix HT-HGU133A chips were used for generation of gene expression data.22  
With 2.5 µg of RNA, synthesis of the cRNA target product, hybridization to the microarray, and 
scanning of the arrays followed Affymetrix manufacturer’s protocols.  Reagents and products 
associated with the GeneChip assay were used in 96-well plate format and the plate was 
scanned with the Affymetrix HT scanner.  Scanned data was converted to average difference 
values using MAS 5.0 (Affymetrix), as described in Supplementary Methods. 
 
BAC array data processing.  
Previously reported BAC array CGH primary melanoma data26 was downloaded from the GEO 
database (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2631).  The genomic 
markers were converted from hg16 to hg17 using the UCSC genome browser 
(http://genome.ucsc.edu/cgi-bin/hgLiftOver). Log2-ratio values were smoothed using the GLAD 
segmentation algorithm.  BAC markers in regions of known copy number polymorphisms were 
removed (http://projects.tcag.ca/variation/) prior to downstream analysis. 
 
Genomic Identification of Somatic Targets in Cancer (GISTIC) analysis.   
Details of the GISTIC algorithm are described elsewhere (Beroukhim et al., submitted).  Briefly, 
each SNP array or CGH data set is defined in terms of copy-number values for N markers along 
the genome in M tumor samples.  To identify significant regions of amplification and deletion, 
the GISTIC algorithm considers both the frequency F of an amplification or deletion above (or 
below) a certain threshold, and the amplitude of that alteration A beyond a certain threshold 
defined by normal samples. Thereby, a genome significance score (G score) G = F x A is 
defined over N markers for all M samples.  At each marker n the computed metric G is 
compared to the null hypothesis – a background metric defined by permutation testing across all 
the markers.  Correcting for multiple hypotheses, we generate a false-discovery rate (q-value) at 
each marker n, aggregating information from M samples.  Using segmented copy number data 
from each sample, the minimal common region of overlap is used to define boundaries of peaks 
in the distribution of q-values. A “wide peak” boundary is determined by samples remaining after 
leaving out the individual samples that define the borders of the “narrow peak.” This wide peak 
reduces the influence of individual samples in dictating peak borders.  
 
Inference of Loss-of-heterozygosity.  
A Hidden Markov Model from dChipSNP software (August 16, 2006 build) that considers 
haplotype information was used to infer LOH calls as described previously30 (Supplementary 
Methods).  
 
Hierarchical clustering using genomic alterations.  
An input binary matrix generated from the GISTIC algorithm (see above).  For each lesion 
defined by GISTIC, a “1” was assigned to a lesion i in a given sample j if the middle marker in 
the lesion i region exceeded the designated log2 threshold of 0.3 for amplifications, or -0.3 for 
deletions. Otherwise, that cell ij was assigned a “0.”  Hierarchical clustering42 with Euclidean 
distance and complete linkage was applied to this matrix using the GenePattern software 
package.43 
 
Significance Analysis of Microarrays (SAM).   
SAM was performed using TIGR MeV 4.0 (http://www.tm4.org/mev.html) to identify differentially 
expressed genes associated with chromosome 10 copy number loss.  Samples were first 
grouped into 3 classes based on mean log 2 copy number over chromosome 10 ( >-0.16, -0.16> 
>-0.44, and <-0.44).  Thresholds were chosen based on a 33 and 67 percentile of copy number 
distribution.  Calculations were done with K-nearest neighbors imputer, 10 neighbors, 100 
permutations and the Tusher method44 to select S0. 
 
Pharmacologic growth inhibition assays.  
Cultured melanoma cells were added to 96-well plates at a concentration of 1,000 (A375 and 
MCF7) and 3,000 (all short-term melanoma cultures and the MALME 3M cell line) cells per well. 
Cells were allowed to adhere overnight, and media containing serial dilutions of CI-1040 (from 
100µM to 1x10-6 µM) was added.  Cells were incubated for 96 hours, at which time cell viability 
was measured using the CellTiter-Glo viability assay (Promega). Viability was calculated as a 
percentage of untreated control values after background subtraction. 
 
Western blotting and biochemical studies.   
After cell lysis (Supplementary Methods), Western blot analysis was performed using primary 
antibodies against p-Erk (anti-phospho-p44/42), total ERK (anti-p44/42), p-MEK (anti-phospho-
MEK1/2 (Ser217/221)), total MEK (anti-MEK1/2) (Cell Signaling Technology), Cyclin D1 (sc-
20044, Santa Cruz Biotechnology), and alpha-tubulin (anti-alpha-tubulin, Cell Signaling 
Technology). All primary antibodies were used at a 1:1000 dilution. The secondary antibody was 
anti-rabbit IgG, HRP-linked (Cell Signaling Technology) at a 1:1000 dilution.  Biochemical MEK 
inhibition by CI-1040 was examined by treating subconfluent melanoma cells with varying 
dilutions of CI-1040 for 24 hours.  After harvest and protein preparation, Western blotting with 
performed with the p-ERK and total ERK antibodies described above. 
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Figure 1: Significant copy number and LOH alterations in melanoma 
Statistically significant genomic amplifications (a) and deletions (b) pinpointed by GISTIC 
analysis of 89 cultured melanoma lines (dark red and dark blue, respectively) and 70 primary 
cutaneous melanomas (orange and light blue, respectively) are shown.  Top axis: FDR-
corrected q-values (threshold FDR=0.25; green line), left axis: chromosome, bottom axis: G-
score (see text).  (c) GISTIC plot of inferred loss-of-heterozygosity (gray) is superimposed onto 
the chromosome deletion plot from (b) (dark blue) in cultured melanoma lines. Selected known 
melanoma oncogenes are indicated. 
 
Figure 2. Clustering analysis of significant melanoma genomic alterations 
Hierarchical clustering of GISTIC lesions (discretized smooth copy number; see Methods) by 
the Euclidean distance metric and complete linkage is shown.  Rows: genomic lesions identified 
by GISTIC algorithm (see text); columns: samples.  Red = presence and blue = absence of 
lesions denoted by cytobands (A = amplification; D = deletion; right).  Mutation status of BRAF 
and NRAS are noted above the matrix. Major clusters are indicated by boxes labeled 1-4. 
 
Figure 3: Integrative analysis of chromosome 10 deletions in melanoma 
(a) Heatmap view of smoothed 250K SNP array data spanning the PTEN locus (red = copy 
gains; blue = copy losses. Samples (columns) are sorted based on copy number values derived 
from segmented data.  (b) PTEN gene expression values stratified according to homozygous 
deletion, hemizygous loss or retention of the underlying locus.  (c) Summary of PTEN protein 
levels in relation to chromosomal deletions affecting the PTEN locus.  (d) Significance analysis 
of melanoma gene expression data.  Samples are stratified according loss or retention at 
chromosome 10 (See Methods).  The positions of CUL2, KLF6, and PTEN are shown. 
 
Figure 4.  Molecular modifiers of MAP kinase dependency in melanoma 
(a) Pharmacologic GI50 values for the MEK inhibitor CI-1040.  Mutation status for BRAF and 
NRAS genes, genomic status at the PTEN locus, and PTEN protein levels are indicated. (b) 
GI50 values for two short-term cultures harboring FGFR1 mutations are shown alongside a 
control melanoma cell line (A375).  (c) Western blot analyses of p-ERK, total ERK, p-MEK, total 
MEK and α-tubulin are shown for selected melanoma lines (CI-1040 GI50 values are indicated).   
 
 
Table 1: Significant regions of amplification in cultured melanoma lines 
 
Chr Cytoband Q-value Narrow peak Wide peak Genes in Wide Region 
Genes of 
Interest 
1 1q21.3  1.48E-10 chr1:148,640,000-148,816,000 chr1:147,610,000-149,170,000 43  
3 3p13    9.36E-17 chr3:70,040,000-70,120,000 chr3:69,870,000-70,220,000 1 MITF 
5 5p15.33 1.37E-01 chr5:360,000-880,000 chr5:1-1680,000 21 TERT 
6 6p25.1  5.70E-08 chr6:5,040,000-5,070,000 chr6:4,070,000-5,620,000 7  
7 7q34    5.07E-26 chr7:139,030,000-140,090,000 chr7:139,030,000-140,480,000 12 BRAF 
7 7p22.3  7.09E-17 chr7:2,560,000-2,760,000 chr7:2,340,000-3,100,000 7  
8 8q24.21 3.77E-04 chr8:130,710,000-131,200,000 chr8:125,960,000-131,360,000 11 MYC? 
11 11q13.3 6.47E-04 chr11:68,800,000-69,060,000 chr11:68,680,000-69,320,000 6 CCND1 
12 12p12.1 1.08E-01 chr12:23,210,000-23,670,000 chr12:22,710,000-23,670,000 2  
15 15q26.1 2.06E-05 chr15:88,690,000-88,890,000 chr15:87,510,000-89,110,000 26  
17 17q25.3 2.03E-07 chr17:75,860,000-76,610,000 chr17:74,750,000-77,010,000 26  
20 20q13.2 2.50E-18 chr20:49,230,000-49,880,000 chr20:49,120,000-50,620,000 4 NFATC2? 




Table 2: Significant regions of deletion in cultured melanoma lines 
 







3 3p26.1   1.21E-01 chr3:4,240,000-4,320,000 chr3:3,820,000-4,470,000 3  
4 4q34.3   9.97E-09 chr4:182,750,000-182,840,000 chr4:182,670,000-182,960,000 0  
5 5q34     1.53E-03 chr5:166,130,000-166,300,000 chr5:165,720,000-166,380,000 0  
6 6q26     2.80E-09 chr6:163,090,000-163,340,000 chr6:162,830,000-163,450,000 2 PACRG, PARK2? 
8 8p23.1   2.96E-03 chr8:6,800,000-6,900,000 chr8:6,800,000-6,950,000 3  
9 9p21.3   8.50E-72 chr9:21,980,000-22,020,000 chr9:21,940,000-220,320,000 2 CDKN2A 
10 10q23.31 1.10E-12 chr10:89,670,000-89,850,000 chr10:89,530,000-89,890,000 2 PTEN 
10 10p15.2  1.22E-10 chr10:3,100,000-3,170,000 chr10:1,330,000-4,630,000 4 KLF6? 
11 11q23.1  1.30E-07 chr11:111,920,000-111,970,000 chr11:111,820,000-112,160,000 0  
13 13q31.1  1.90E-03 chr13:84,620,000-85,090,000 chr13:84,560,000-96,340,000 16  
14 14q32.2  3.05E-02 chr14:97,930,000-98,100,000 chr14:97,610,000-98,100,000 0  
15 15q21.1  6.22E-02 chr15:42,830,000-42,920,000 chr15:42,720,000-43,420,000 13  
16 16q23.2  6.04E-02 chr16:78,590,000-78,830,000 chr16:78,410,000-78,920,000 0  
18 18q22.1  1.03E-02 chr18:62,660,000-63,040,000 chr18:62,660,000-72,570,000 24  
 
